{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.04","value":"455.86"},{"groupId":"OG001","spread":"31.00","value":"897.43"},{"groupId":"OG002","spread":"39.215","value":"921.87"},{"groupId":"OG003","spread":"25.57","value":"1502.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal renal function (defined as creatinine clearance \\> 80 mL/min/1.73m\\^2) received a single subcutaneous dose of azacitidine 25 mg/m\\^2 on Day 1.","id":"OG000","title":"Azacitidine 25 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\\^2 on Day 1.","id":"OG001","title":"Azacitidine 50 mg/m^2"},{"description":"Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"OG002","title":"Azacitidine 75 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\\^2 on Day 1.","id":"OG003","title":"Azacitidine 100 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) Population, consisting of all participants with evaluable plasma or urine concentration data for azacitidine. This analysis was performed for participants with normal renal function only.","reportingStatus":"POSTED","timeFrame":"Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose","title":"Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose","type":"PRIMARY","unitOfMeasure":"ng*hr/mL"}